Cart
sales@molnova.com
DHMB
CAS No. 4055-69-0
DHMB( 2,3-Dihydroxy-4-Methoxybenzaldehyde )
Catalog No. M27382 CAS No. 4055-69-0
DHMB exerts protective effects on intestinal epithelial cells. DHMB exhibits anti-inflammatory and antifungal capacity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 160 | In Stock |
|
| 2MG | 121 | In Stock |
|
| 5MG | 202 | In Stock |
|
| 10MG | 330 | In Stock |
|
| 25MG | 524 | In Stock |
|
| 50MG | 709 | In Stock |
|
| 100MG | 918 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | 1841 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameDHMB
-
NoteResearch use only, not for human use.
-
Brief DescriptionDHMB exerts protective effects on intestinal epithelial cells. DHMB exhibits anti-inflammatory and antifungal capacity.
-
DescriptionDHMB exerts protective effects on intestinal epithelial cells. DHMB exhibits anti-inflammatory and antifungal capacity.
-
In Vitro——
-
In Vivo——
-
Synonyms2,3-Dihydroxy-4-Methoxybenzaldehyde
-
PathwayOthers
-
TargetOther Targets
-
RecptorApoptosis
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number4055-69-0
-
Formula Weight168.148
-
Molecular FormulaC8H8O4
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCOc1ccc(C=O)c(O)c1O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Kim T, Kim YJ, Han IH, Lee D, Ham J, Kang KS, Lee JW. The synthesis of sulforaphane analogues and their protection effect against cisplatin induced cytotoxicity in kidney cells. Bioorg Med Chem Lett. 2015 Jan 1;25(1):62-6. doi: 10.1016/j.bmcl.2014.11.014. Epub 2014 Nov 11. PMID: 25466193.
molnova catalog
related products
-
TRH-SH Pro
TRH-SH Pro
-
Compound V007-6018
Compound V007-6018 is a pharmaceutical compound used for drug screening.
-
BV02
BV02 is an inhibitor of 14-3-3 protein-protein interactions and can be used in studies about the treatment of chronic myeloid leukemia. BV02 disrupts hematopoietic cells expressing the IM-resistant T315I mutation and the IM-sensitive wild-type Bcr-Abl.
